Abstract
Aim:
To investigate the antiproliferative activity and apoptosis-inducing effects of bufalin on human osteosarcoma cell lines.
Methods:
U-2OS and U-2OS methotrexate (MTX) 300-resistant cell lines were treated with bufalin. Cell viability was assessed using the MTT assay. Cell-cycle status, apoptosis-inducing effects, and the expression of apoptosis-related proteins were evaluated by flow cytometry, fluorescent staining, DNA fragmentation assays, and Western blotting. The effect of bufalin on dihydrofolate reductase (DHFR) expression was studied by RT-PCR and Western blotting.
Results:
Bufalin inhibited cell growth in both U-2OS and U-2OS MTX300 cells. The induction of G2/M cell-cycle arrest was also seen in the cells treated with bufalin. The induction of apoptosis by bufalin was confirmed by increased expression of the tumor suppressor protein p53 and the increased ratio of the Bax/Bcl-2 proteins. Bufalin induced apoptosis to the same extent in both cell lines without regard to DHFR levels in the cells.
Conclusion:
Bufalin inhibited the growth of and induced apoptosis in both MTX-sensitive and MTX-resistant human osteosarcoma U-2OS cells. The apoptosis-inducing effect of bufalin was not influenced by the presence of high levels of the DHFR protein.
Similar content being viewed by others
Article PDF
References
Ferguson WS, Goorin AM . Current treatment of osteosarcoma. Cancer Invest 2001; 19: 292–315.
Bramwell VH . Osteosarcomas and other cancers of bone. Curr Opin Oncology 2000; 12: 330–6.
Davis AM, Bell RS, Goodwin PJ . Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994; 12: 423–31.
Uchida A, Myoui A, Araki N, Yoshikawa H, Shinto Y, Ueda T . Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer 1997; 79: 411–5.
Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 1991; 270: 8–14.
Bertino JR, Goker E, Gorlick R, Li WW, Banerjee D . Resistance mechanisms to methotrexate in tumors. Stem Cells 1996; 14: 5–9.
Slansky JE, Li Y, Kaelin WG, Farnham PJ . A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol 1993; 13: 1610–8.
Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR . Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002; 1587: 164–73.
Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999; 5: 621–7.
Serra M, Reverter-Branchat G, Maurici D, Benini S, Shen JN, Chano T, et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 2004; 15: 151–60.
Hattinger CM, Reverter-Branchat G, Remondini D, Castellani GC, Benini S, Pasello M, et al. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. Eur J Cell Biol 2003; 82: 483–93.
Panesar NS . Bufalin radioimmunoassays: in search of the endogenous digitalis-like substance. J Immunoassay 1994; 15: 371–91.
Hong Z, Chan K, Yeung HW . Simultaneous determination of bufadienolides in the traditional Chinese medicine preparation, Liu-Shen-Wan, by liquid chromatography. J Pharm Pharmacol 1992; 44: 1023–6.
Krenn L, Kopp B . Bufadienolides from animal and plant sources. Phytochemistry 1998; 48: 1–29.
Watabe M, Kawazoe N, Masuda Y, Nakajo S, Nakaya K . Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. Cancer Res 1997; 57: 3097–100.
Watabe M, Ito K, Masuda Y, Nakajo S, Nakaya K . Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene 1998; 16: 779–87.
Kawazoe N, Watabe M, Masuda Y, Nakajo S, Nakaya K . Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells. Oncogene 1999; 18: 2413–21.
Nasu K, Nishida M, Ueda T, Takai N, Bing S, Narahara H, et al. Bufalin induces apoptosis and the G0/G1 cell cycle arrest of endometriotic stromal cells: a promising agent for the treatment of endometriosis. Mol Hum Reprod 2005; 11: 817–23.
Yeh JY, Huang WJ, Kan SF, Wang PS . Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 2003; 54: 112–24.
Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, De Giovanni C, et al. Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. Anticancer Res 1993; 13: 323–9.
Rui H . Research and development of cancer chemopreventive agents in China. J Cell Biochem Suppl 1997; 27: 7–11.
Numazawa S, Shinoki M, Ito H, Yoshida T, Kuroiwa Y . Involvement of Na+,K+-ATPase inhibition in K562 cell differentiation induced by bufalin. J Cell Physiol 1994; 160: 113–20.
Jing Y, Ohizumi H, Kawazoe N, Hashimoto S, Masuda Y, Nakajo S, et al. Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: association with the induction of apoptosis in leukemia HL-60 cells. Jpn J Cancer Res 1994; 85: 645–51.
Jing Y, Watabe M, Hashimoto S, Nakajo S, Nakaya K . Cell cycle arrest and protein kinase modulating effect of bufalin on human leukemia ML1 cells. Anticancer Res 1994; 14: 1193–98.
Borner C . The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003; 39: 615–47.
Miyashita T, Reed JC . Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293–9.
Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL . The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 2002; 277: 16 547–52.
Ryan KM, Phillips AC, Vousden KH . Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 2001; 13: 332–7.
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R . Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–25.
Salomons GS, Brady HJ, Verwijs-Janssen M, van Den Berg JD . Hart AA, van Den Berg H, et al. The Bax alpha: Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int J Cancer. 1997; 71: 959–65.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by grants from the Cooperation Foundation of Sun Yat-Sen University (No 162004), the National Natural Science Foundation of China (No 30200285) and Natual Science Foundation of Guangdong Province (No 4009423).
Rights and permissions
About this article
Cite this article
Yin, Jq., Shen, Jn., Su, Ww. et al. Bufalin induces apoptosis in human osteosarcoma U-2OS and U-2OS methotrexate300-resistant cell lines. Acta Pharmacol Sin 28, 712–720 (2007). https://doi.org/10.1111/j.1745-7254.2007.00559.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00559.x
Keywords
This article is cited by
-
Chromosomal translocation-derived aberrant Rab22a drives metastasis of osteosarcoma
Nature Cell Biology (2020)
-
Targeting the CK1α/CBX4 axis for metastasis in osteosarcoma
Nature Communications (2020)
-
Artificial intelligence method for predicting the maximum stress of an off-center casing under non-uniform ground stress with support vector machine
Science China Technological Sciences (2020)
-
New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin
Cancer Cell International (2019)
-
MicroRNA-497 and bufalin act synergistically to inhibit colorectal cancer metastasis
Tumor Biology (2014)